Core Insights - The Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular event risks in high-risk patients [1] - This approval represents the eighth national reimbursement of VAZKEPA in Europe, enhancing its market presence [1] - The commercialization of VAZKEPA in Portugal will commence on August 1, 2024, providing a new treatment option for patients with established cardiovascular disease [1] Company Overview - Amarin Corporation is focused on innovative pharmaceutical solutions for cardiovascular disease management, with a commitment to addressing cardiovascular risks beyond traditional therapies [1] - The company has a strong intellectual property position for VAZKEPA in Europe, extending until 2039 [1] - Amarin is actively pursuing pricing and reimbursement discussions in other European markets to enhance patient access [1] Market Context - In Portugal, the prevalence of established cardiovascular disease among adults aged 45 to 79 is reported at 10.7% [1] - Cardiovascular disease accounts for over 35,000 annual deaths in Portugal, representing 29% of total mortality in 2017 [1] - The growing prevalence of cardiovascular risk factors underscores the urgent need for effective treatment options in the Portuguese healthcare system [1]

Core Insights - Amarin Corporation plc will host a conference call on July 31, 2024, at 8:00 a.m. ET to discuss its second quarter 2024 results [1] - The company is partnering with Say Technologies to allow shareholders to submit and upvote questions for the management during the earnings call [1][2] Conference Call Details - The earnings call will take place following the release of the second quarter 2024 financial results in the pre-market hours on July 31 [1] - Shareholders can submit questions via a dedicated platform until 24 hours before the call [2] - Access to the live call can be found on the investor relations section of Amarin's website, with specific dial-in numbers provided for both U.S. and international participants [3] Company Overview - Amarin is an innovative pharmaceutical company focused on cardiovascular disease management, with offices in multiple countries including the U.S., Ireland, and Switzerland [4] - The company aims to enhance the scientific understanding of cardiovascular risks that persist beyond traditional therapies [4] Investor Communication - Amarin utilizes its website and investor relations section to communicate with investors, providing access to various materials including presentations, SEC filings, and press releases [5] - The company encourages regular review of the information posted on its channels, which may include updates on social media [5]

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China -- DUBLIN and BRIDGEWATER, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Amari ...

Core Viewpoint - Amarin Corporation's commercial partner EddingPharm has received regulatory approval from China's National Medical Products Administration (NMPA) for VASCEPA to reduce the risk of cardiovascular events in specific high-risk adult patients [1][2] Group 1: Regulatory Approval and Market Potential - VASCEPA is approved as an adjunct to statin therapy for adult patients with elevated triglyceride levels (≥150 mg/dL) and established cardiovascular disease or diabetes with additional risk factors [1][2] - EddingPharm is working to include VASCEPA in the National Reimbursement Drug Listing (NRDL), which covers 98% of the Chinese population, allowing for public reimbursement [2] Group 2: Cardiovascular Disease Context in China - Cardiovascular disease (CVD) accounts for 44-47% of all deaths in China, with an estimated 330 million patients suffering from CVD [3] - The World Heart Federation projects a 50% increase in cardiovascular events in China from 2010 to 2030 due to population aging and growth [3] Group 3: Financial Implications and Partnerships - Amarin will receive a regulatory milestone payment of $15 million from EddingPharm following the NMPA approval [4] - EddingPharm will pay Amarin tiered double-digit percentage royalties on net sales of VASCEPA in China [4] Group 4: Future Developments - NMPA has requested EddingPharm to conduct a post-approval study to verify VASCEPA's efficacy in reducing cardiovascular events in Chinese patients [3][4]

Bangkok, Thailand, June 07, 2024 (GLOBE NEWSWIRE) -- LA BOUTIQUE This new location promises to be a premier destination for high-end fashion enthusiasts and tourists visiting Bangkok, Thailand. Celebrating 12 years in the fashion industry, LA BOUTIQUE has consistently pushed the boundaries of design and innovation, creating timeless pieces that captivate audiences worldwide. The brand’s exquisite collections have been worn by international celebrities such as Eva Longoria, Olivia Palermo, and Kristina Baza ...

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as ...

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as ...

Core Points - The Greek Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in high-risk adult patients treated with statins [1][2] - This approval represents the seventh national reimbursement of VAZKEPA® in Europe, enhancing access for eligible patients in Greece [2] - Vianex S.A. has been appointed as the exclusive distributor of VAZKEPA® in Greece, responsible for its import, registration, distribution, and commercialization [3][4] Company Overview - Amarin Corporation is focused on advancing cardiovascular disease management and increasing scientific understanding of cardiovascular risk beyond traditional therapies [5] - Vianex S.A., a leading Greek pharmaceutical company, has a 100-year history in the industry and is known for its strong commercial capabilities and expertise in cardiology [6][7]

Core Points - The Greek Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in high-risk adult patients treated with statins [1][2] - This approval represents the seventh national reimbursement of VAZKEPA® in Europe, enhancing access for eligible patients in Greece [2] - Amarin Corporation has partnered with Vianex S.A. as the exclusive distributor of VAZKEPA® in Greece, with commercialization expected to begin shortly [3][4] Company Overview - Amarin Corporation is focused on advancing cardiovascular disease management and increasing scientific understanding of cardiovascular risk beyond traditional therapies [5] - Vianex S.A. is a leading Greek pharmaceutical company with a 100-year history, involved in the production, import, marketing, and distribution of pharmaceuticals [6][7] Market Context - Cardiovascular diseases are the leading cause of death in Greece, highlighting the importance of new treatment options like VAZKEPA® for improving heart health [2]

DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference. H.C. Wainwright 2nd Annual BioConnect Investor Conference (May 20th, 2024; NYC)Date/Time:May 20, 2024, 4:30 p.m. ETWebcast:https://journey.ct.events/view/a719062a-400f-406f-82d4-2463ef546624   The session ...